- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease; Moderate to severe ulcerative colitis.
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 363KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 48KB)
Adalimumab – November 2021
Adalimumab: Injection 80 mg in 0.8 mL pre-filled syringe; Humira®
Last updated
4 March 2022